CTLA4 and nonpapillary renal cell carcinoma: Since CTLA4 promoter hypomethylation is associated with an enhanced immune infiltrate in ccRCC, assessment of CTLA4 methylation status in treatment-naïve tissue samples prior to initiation of ICB therapy may have predictive value for ICB-treatment success.